Sichuan Kelun Biotech Biopharmaceutical (SEHK:6990) After Profitability And Oncology Progress Looks Undervalued
Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) has drawn fresh attention after reporting a shift to profitability in its half year 2026 results, along with a series of product milestones across its oncology portfolio.
See our latest analysis for Sichuan Kelun-Biotech Biopharmaceutical.
The recent run of clinical milestones, regulatory decisions and the shift to profitability appears to have supported sentiment in Sichuan Kelun-Biotech Biopharmaceutical, with the stock delivering a 13.45% 90 day share price return and a very large 536.31% three year total shareholder return from a HK$538.0 share price today.
If you are comparing Kelun-Biotech’s progress with other oncology and biotech stories, it can help to see what else is moving in related areas, starting with 130 healthcare AI stocks.
After Sichuan Kelun-Biotech Biopharmaceutical’s sharp multi year rerating and a HK$538.0 share price, there is now a clear gap between where the market trades and the range of value estimates. So where might fair value actually sit?
Most Popular Narrative: 9.5% Undervalued
Compared with the HK$538.0 share price, the most widely followed narrative places Sichuan Kelun-Biotech Biopharmaceutical’s fair value higher, using detailed long term earnings and cash flow assumptions.
The broad adoption of antibody drug conjugates in cancer treatment, combined with Kelun-Biotech's OptiDC platform and 9 ADC projects in the clinic, positions the company to add indications and products that can widen the revenue base over time.
Curious what earnings ramp, margin profile and future profit multiple are baked into that higher fair value for Sichuan Kelun-Biotech Biopharmaceutical? The narrative leans on steep revenue expansion, a step change in profitability and a rich outer year earnings multiple that is still framed as reasonable for this kind of growth story.
Result: Fair Value of HK$594.73 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Sichuan Kelun-Biotech Biopharmaceutical still faces meaningful risks, including reliance on long duration ADC and immunotherapy trends, as well as successful execution across 17 global Phase III trials.
Find out about the key risks to this Sichuan Kelun-Biotech Biopharmaceutical narrative.
Another View: Rich Market Multiple For Sichuan Kelun-Biotech Biopharmaceutical
That 9.5% undervalued fair value for Sichuan Kelun-Biotech Biopharmaceutical contrasts with how the market is currently pricing the stock. On a P/B of 20.7x versus 3.6x for the Hong Kong Biotechs industry and 8.7x for peers, the shares look expensive on this yardstick. If the P/B ratio moved closer to a fair ratio in line with sector norms, the gap could mean higher valuation risk than the DCF style narrative implies. Which signal do you put more weight on: the discounted cash flow story or the premium multiple?
To see how those P/B numbers fit into a fuller breakdown that compares Sichuan Kelun-Biotech Biopharmaceutical with its industry and peers, take a look at the See what the numbers say about this price — find out in our valuation breakdown..
Next Steps
With both optimism and caution running through this Sichuan Kelun-Biotech Biopharmaceutical story, it makes sense to move quickly and test the assumptions for yourself using the full breakdown of 3 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Sichuan Kelun-Biotech Biopharmaceutical?
If you want a broader watchlist around Sichuan Kelun-Biotech Biopharmaceutical, use the Simply Wall St screener to quickly spot fresh ideas that fit your style.
- Target consistent income potential by reviewing dependable payers in the 424 dividend fortresses.
- Hunt for quality at a measured price through the 269 high quality undervalued stocks.
- Prioritise resilience and capital protection by checking companies in the 295 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com